SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

P. Nathan, A. Needham, P. G. Corrie, S. Danson, J. Evans, S. Ochsenreither, S. Kumar, A. Goodman, J. M. G. Larkin, I. Karydis, N. M. Steven, P. Lorigan, R. Plummer, P. Patel, H. M. Shaw, S. Leyvraz, C. Rawcliffe, E. E. Psarelli, L. Handley, J. J. Sacco

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
JournalAnnals of Oncology
Publication statusPublished - Oct 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this